Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, researchers at a Spanish hospital found that the severity of frontal fibrosing alopecia, primarily affecting postmenopausal women, was correlated with the duration of the disease, though inflammatory signs were not linked with its progression.

This study found that finasteride use is associated with both known and new adverse events, which vary by gender and age, as well as some events not previously listed in the drug insert.

This case report describes a child with acrodermatitis enteropathica showing dramatic improvement with oral zinc therapy, highlighting the importance of early diagnosis and treatment to prevent severe outcomes.

This study observed that patients with AA showed a high willingness to trade off lifespan for better disease-specific quality of life, indicating a significant disease burden.

This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.

This correspondence discusses proposed updates to the diagnostic criteria for frontal fibrosing alopecia, emphasizing the importance of differentiating it from other types of alopecia.

This study suggests that Equisetum debile extracts, particularly the ethyl acetate fraction, may offer natural cosmeceutical benefits for treating hyperpigmentation, delaying skin aging, and remediating hair loss due to androgenic alopecia.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study suggests that pilose antler extracts promote hair regrowth in androgenetic alopecia mice by activating the AKT and Wnt pathways, enhancing hair follicle stem cell proliferation.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

This article reviews the effectiveness of adrenal cortex compounds E and F in treating various connective tissue disorders and reports no new clinical findings.

This study found that genetic ablation of Tslp in an AEC mutant mouse model reduced skin inflammation and improved survival, suggesting potential therapeutic benefits for AEC syndrome patients.

The study found that cyproterone acetate could be released over 15 days using coconut oil mixed with certain wax inhibitors, though further safety studies are needed.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This study found that Facia Men’s capsule significantly reduced hair shedding in men with androgenetic alopecia over 12 weeks, without notable renal or liver safety concerns.

This correspondence discusses the diagnostic criteria for frontal fibrosing alopecia but reports no new research findings, agreeing with many previously suggested criteria.

This study observed that trichoscopic changes associated with EGFRI treatment include pili torti and asymmetric hyperpigmented fusiform widening, along with dermoscopic skin manifestations such as scale and branching vessels.

This research abstract outlines the innovative approach of the Frontiers journal series, which aims to transform academic publishing by providing open access, interdisciplinary journals that employ a rigorous peer-review process to serve both scholarly communities and the public.

In this study, AMACO was found to be non-essential for the formation or function of anchoring cords in mice, despite its presence in the structure.

This study found that EGFR signaling modulates GLI target gene expression, potentially influencing outer root sheath cell specification and hair growth, and may have implications for cancer.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.

This study discusses how chronic ethanol exposure and withdrawal affect GABAA receptor subunit expression and function, finding that some changes can be selectively blocked by certain drugs like diazepam and finasteride.

This article reviews the increasing incidence of frontal fibrosing alopecia since its first description in 1994 and reports no new results.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

Contact allergies might contribute to frontal fibrosing alopecia.

This case study reports successful treatment of frontal fibrosing alopecia with daily 2.5mg finasteride in a 77-year-old woman.